Antidote for potassium toxicity8/17/2023 ![]() That’s why the company built a regulatory infrastructure and a network of distributors that would allow us to make its products available throughout the world. In the field of emergency medicine, each second counts so, there are added challenges in consistently supplying these essential medicines and ensuring they are stocked close to where they may be needed. Over the past 25 years, the company expanded its portfolio in emergency medicine and (especially) antidotes. That is at the core of SERB’s culture and growth strategy. The company has always been focused on essential, niche treatments that meet high medical needs. Hill: SERB (Society for Biological Studies and Research) was founded in France in 1951 by two pharmacists. What got the company into this line of work? Pharm Exec: SERB Pharmaceuticals has a large antidote portfolio. They believe in our mission and have supported our investment in acquiring and developing new antidotes. Since 2017, SERB has been majority owned by Charterhouse Capital, one of the longest-established private equity firms operating in Europe. In 2021, the European Commission launched an agency with a similar purpose called the European Health Emergency Preparedness and Response Authority (HERA). In the US, this comes from groups such as the Biomedical Advanced Research and Development Authority (BARDA), which is tasked with preparing medical countermeasures for public health emergencies. Hill: One difference is that promising research is more likely to attract public funding. ![]() Pharm Exec: How does acquiring financial backing differ for the antidotes market vs. Therefore, it is essential for us to work with our partners all along the supply chain to ensure the availability of our products. ![]() The key difference lies in the channels used once produced to ensure that the antidote is there when needed. All of our medical countermeasures for CBRN (chemical, biological radiological, and nuclear), including the active ingredients, are made in Europe, which is important to our government and military customers. Continuity of supply and supply chain resilience is also of added importance when you are providing antidotes. Quality is important for any medicinal product, but even more for critical care and antidotes products. There are very few major differences in manufacturing. For example, take exposure to cyanide-we rely on FDA’s ‘animal rule’ and similar pathways in other jurisdictions. For example, we could not ethically test an antidote in human efficacy trials. Hill: Development pathways can be slightly different. traditional bio/pharmaceuticals (if at all)? Pharm Exec: How do the development and manufacturing differ for antidotes vs. This will require close cooperation between public bodies, NGOs, subject matter experts, and private companies with relevant experience and capabilities. Everyone is trying to predict the next threat (which is difficult) and put things in place to be able to react to a range of threats. Developing antidotes and securing the capabilities to respond quickly to new pathogens have taken on a renewed urgency for governments around the world. We’ve also seen greater interest in our development projects. ![]() In 2022, we doubled our manufacturing capability to meet these unexpected needs. We saw a huge increase in demand for these products from both governments and the public in reaction to the conflict in Ukraine-especially fighting around Chernobyl and the Zaporizhzhia nuclear power plant. Typically, these are stocked by those living near nuclear reactors as a precaution. To take one example-we sell potassium iodide products that prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. Those responsible for emergency planning are more conscientious about what they stockpile and what antidotes they may want to have on hand in a public health emergency. Hill: Having been in this field for 20 years, we’ve seen how the COVID pandemic, the war in Ukraine, and (more recently) reports of terrorist activity in Western Europe have put health emergency preparedness and response higher on the agenda of governments, public health agencies, and militaries around the world. What does that look like in 2023? Do you anticipate an increased demand? Pharm Exec: Let’s talk about the demand for antidotes. In this exclusive Q&A with Pharmaceutical Executive, Christon Hill, chief innovation officer, SERB Pharmaceuticals, reveals the demand for antidotes, how the development and manufacture of antidotes differ from “traditional” pharmaceuticals, acquiring financial backing, antidotes the company is working on, and more. ![]() But one market that may not be discussed as often as others is that of antidotes and the treatment of poisonings, toxicities, and more. There are many important markets in the pharmaceutical industry that address patient needs. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |